| Literature DB >> 22028979 |
Mahrukh Fatima1, Pashtoon Murtaza Kasi, Shahnaz Naseer Baloch, Masoom Kassi, Shah Muhammad Marri, Mahwash Kassi.
Abstract
Molar pregnancies represent a significant burden of disease on the spectrum of gestational trophoblastic diseases. The incidence appears to be higher in women from South Asia. The purpose of our prospective study was to determine the incidence, presentation, and outcomes of all molar pregnancies at our institution. During the study period, there were a total of 16,625 patients admitted to our department; out of whom 85 patients were diagnosed with a molar pregnancy. Vaginal bleeding was the commonest symptom (94.2%); theca lutein cysts were noted in 39% of the cases. Suction, dilatation, and curettage were noted to be the preferred method in almost all cases; hysterectomy was done in 12 (14.1%) patients. Single-agent chemotherapy was employed in high-risk patients and was well tolerated. Mean followup for these patients was 5.7 months (range 1-24 months). None of these patients developed persistent trophoblastic disease, invasive mole, or choriocarcinoma during the follow-up period.Entities:
Year: 2011 PMID: 22028979 PMCID: PMC3195536 DOI: 10.5402/2011/925316
Source DB: PubMed Journal: ISRN Obstet Gynecol ISSN: 2090-4436
Basic Demographics, incidence of hydatidiform mole, and associated factors.
| Number of cases | % | ||
|---|---|---|---|
| (1) | 85 | 0.51% | |
|
| |||
| (2) | |||
| <5,000 (~$60) | 70 | 82.4% | |
| 5,000–10,000 ($60–120) | 14 | 16.5% | |
| >10,000 ($120) | 1 | 1.1% | |
|
| |||
| (3) | |||
| 0 | 31 | 36.5% | |
| 1–4 | 29 | 34.1% | |
| 5-17 | 25 | 29.4% | |
|
| |||
| (4) | |||
| Less than 6 cm | 18 | 21.2% | |
| ≥6 cm | 15 | 17.6% | |
| Not detected | 52 | 61.2% | |
|
| |||
| (5) | |||
| Corresponding to the gestational age | 10 | 11.7% | |
| 4–12 weeks more than the gestational age | 60 | 70.6% | |
| >12 weeks | 15 | 17.7% | |
|
| |||
| (6) | |||
| Amenorrhea | 85 | 100% | |
| Vaginal Bleeding | 80 | 94.2% | |
| Hyperemesis | 8 | 9.4% | |
| Preeclempsia | 10 | 11.8% | |
|
| |||
| (7) | |||
| ≤8 | 4 | 4.7% | |
| 9–12 | 22 | 25.9% | |
| 13–20 | 51 | 48.2% | |
| >20 | 18 | 21.2% | |
|
| |||
| (8) | 58 | 68.2% | |
|
| |||
| (9) | 1 | 1.2% | |
Diagnosis, management of HM, and associated complications.
| Number of cases | % | ||
|---|---|---|---|
| (1) | |||
| Sonographic findings | 73 | 79.5% | |
|
| 85 | 100% | |
| Histopathology | 85 | 100% | |
|
| |||
| (2) | |||
| <50,000 | 12 | 14.1% | |
| 50,000–100,000 | 53 | 62.4% | |
| >100,000 | 20 | 23.5% | |
|
| |||
| (3) | |||
| Suction/sharp curettage | 62 | 72.9% | |
| Oxytocin/curettage | 10 | 11.8% | |
| Hysterectomy | 12 | 14.1% | |
| Prostaglandins/curettage | 1 | 1.2% | |
|
| |||
| (4) | |||
| None | 12 | 14.1% | |
| Up to 1 week | 60 | 70.6% | |
| 2–3 weeks | 12 | 14.1% | |
| ≥4 weeks | 1 | 1.2% | |
|
| |||
| (5) | 85 | 100% | |
|
| |||
| (6) | 22 | 25.8% | |
|
| |||
| (7) | 2 | 2.4% | |
|
| |||
| (8) | 1 | 1.2% | |
|
| |||
| (9) | 2 | 2.4% | |
|
| |||
| (10) | |||
| Sharp regression | 66 | 94.3% | |
| Slow regression | 2 | 2.9% | |
| Plateau | 1 | 1.4% | |
| Rising | 1 | 1.4% | |
|
| |||
| Sharp regression | 3 | 20% | |
| Slow regression | 12 | 80% | |